Activated protein C resistance in young adults with central retinal vein occlusion

British Journal of Ophthalmology

Volumn 80, Issue 3, 1996, Pages 200-202

  Larsson, J ^a   Olafsdottir, E ^b   Bauer, B ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b ÖREBRO MEDICAL CENTRE HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIVATED PROTEIN C;

ACTIVATED PROTEIN C RESISTANCE; ADULT; AGE; ANTICOAGULATION; ARTICLE; ATHEROSCLEROSIS; BLOOD CLOTTING; CENTRAL RETINA VEIN OCCLUSION; CLINICAL ARTICLE; DIABETES MELLITUS; DISEASE ASSOCIATION; FEMALE; GLAUCOMA; HUMAN; HYPERTENSION; MALE; PRIORITY JOURNAL;

EID: 0029927375     PISSN: 00071161     EISSN: None     Source Type: Journal    
DOI: 10.1136/bjo.80.3.200     Document Type: Article

References (18)

1. McGrath MA, Wechsler F, Hunyor ABL, Penny R. Systemic factors contributory to retinal vein occlusion. Arch Intern Med 1978; 138: 216-20.
2. Fong AC, Schatz H, McDonald HR, Burton TC, Maberley AL, Joffe L, et al. Central retinal vein occlusion in young adults (papillophlebitis). Retina 1991; 11: 3-11.
3. Walters RF, Spalton DJ. Central retinal vein occlusion in people aged 40 years or less: a review of 17 patients. Br J Ophthalmol 1990; 74: 30-5.
4. Fong AC, Schatz H. Central retinal vein occlusion in young adults. Surv Ophthalmol 1993; 37: 393-417.
5. Priluck IA, Robertson DM, Hollenhorst RW. Long term follow-up of occlusion of the central retinal vein in young adults. Am J Ophthalmol 1980; 90: 190-202.
6. Malm J, Laurell M, Nilsson IM, Dahlbäck B. Thromboembolic disease - critical evaluation of laboratory investigation. Thrombosis and Haemostasis 1992; 68: 7-13.
7. Taberno MD, Tomas JF, Alberca I, Orfao A, Borrasca AL, Vicente V. Incidence and clinical characteristics of hereditary disorders associated with venous thrombosis. Am J Hematol 1991; 36: 249-54.
8. Davie ED, Fujikawa K, Kisiel W. The coagulation cascade: initiation, maintenance and regulation. Biochemistry 1991; 30: 10363-70.
9. Svensson PJ, Dahlbäck B. Resistance to activated protein C as a basis for venous thrombosis. N Engl J Med 1994; 330: 517-22.
10. Dahlbäck B, Carlsson M, Svensson PJ. Familial thrombophilia due to a previously unrecognized mechanism characterized by poor anticoagulant response to activated protein C: prediction of a cofactor to activated protein C. Proc Natl Acad Sci USA 1993; 90: 1004-8.
11. Dahlbäck B, Svensson PJ. Nyupptäckt rubbning i antikoagulationen. resistens mot protein C orsak till trombos. Läkartidningm 1994; 91: 50-3.
12. Dahlbäck B, Hildebrand B. Inherited resistance to activated protein C is corrected by anticoagulant cofactor activity found to be a property of factor V. Proc Natl Acad Sci USA 1994; 91: 1396-400.
13. Bertina RM, Koeleman BPC, Koster T, Rosendaal FR, Dirven RJ, de Ronde H, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. [Letter] Nature 1994; 369: 64-7.
14. Greengard JS, Xiao Xiu XS, Fernandez JA, Griffin JH, Evatt B. Activated protein C resistance caused by Arg506Gln mutation in factor Va. Lancet 1994; 343: 1361-2.
15. Lindblad B, Svensson PJ, Dahlbäck B. Arterial and venous thromboembolism with fatal outcome and resistance to activated protein C. Lancet 1994; 343: 917.
16. Koster T, Rosendaal FR, de Ronde H, Briet E, Vandenbroucke JP, Bertina RM. Venous thrombosis due to poor anticoagulant response to activated protein C: Leiden thrombophilia study. Lancet 1993; 342: 1503-6.
17. Legnani C, Palareti G, Biagi R, Coccheri S. Activated protein C resistance in deep vein thrombosis. Lancet 1994; 343: 541-2.
18. Ie D, Lipkowitz JL, Pennacchi J. Resistance to activated protein C as a basis for central retinal vein thrombosis. Invest Ophthalmol Vis Sci (ARVO supplement) 1995; 36: 619.